Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
6
×
Tags
boston blog main
boston top stories
national blog main
national top stories
new york blog main
new york top stories
6
×
praluent
6
×
san francisco blog main
san francisco top stories
6
×
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
raleigh-durham blog main
raleigh-durham top stories
regeneron pharmaceuticals
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
sanofi
amgen
cholesterol
fda
inclisiran
pcsk9
rejection
repatha
abeona therapeutics
affordable care act
agios pharmaceuticals
What
bio
healthcare
roundup
cholesterol
american
based
best
continue
crash
debate
drug
industry
kind
lowering
nash
people
pharmaceutical
policy
politicians
pressure
scalps
trump’s
u.s
week
abbvie’s
aces
america
announced
barbecuing
big
biogen
camping
cardiologist
center
ceo
check
conference
continues
convoluted
day
Language
unset
Current search:
praluent
×
photo
×
" new york top stories "
×
" san francisco top stories "
×
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
4 years ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More